Preliminary data shows that the mRNA-1273 vaccine generates immune response to SARS-COV2 without serious adverse effects, thereby supporting further development of this vaccine.
16 July 2020
Many clinical trials for vaccine development are underway to combat the Covid-19 pandemic. One of these candidate vaccines, called mRNA-1273, generates antibodies to the spike proteins surrounding the outside of the coronavirus. To see whether this vaccine could generate an effective antibody response in humans, researchers provided 45 healthy human volunteers with two vaccinations given 28 days apart at three different doses: 25 μg 100 μg, and 250 μg. Each vaccination group had 15 participants. The mRNA-1273 was able to induce an immune response in all participants in all dosing groups. No serious adverse events were reported from the study. While the study is small and provides only preliminary data, its findings are promising and support further clinical trials to support the development of the mRNA-1273 vaccine.
Summary by: Louis Huynh